eligibility_summary
Adults ≥18 with high-grade serous/endometrioid ovarian, primary peritoneal, or fallopian tube cancer, measurable disease, biopsy, 1–3 prior lines, bevacizumab given, platinum-resistant, prior PARP if BRCA, prior mirvetuximab if FRα+, ECOG 0–1, contraception if fertile. Exclude other histologies, inadequate washout, CNS mets, major CV or lung disease/ILD, chronic steroids, unresolved tox, prior CDH6 or exatecan-ADC, uncontrolled HIV/HBV/HCV, pregnancy, live vaccine. Phase 3: eligible for, not previously given, investigator-choice chemo.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial: NCT06161025. Testing raludotatug deruxtecan (R-DXd, DS-6000a), a CDH6-directed antibody–drug conjugate (ADC). Mechanism: the monoclonal antibody binds Cadherin-6 (CDH6) overexpressed on ovarian/peritoneal/fallopian tube cancer cells, is internalized, and releases a deruxtecan (DXd) payload, a membrane-permeable topoisomerase I inhibitor (exatecan derivative) that causes DNA damage and apoptosis. Part A optimizes dose (4.8/5.6/6.4 mg/kg Q3W), Part B compares RP3D vs investigator’s choice chemo. Comparators and mechanisms: paclitaxel (taxane, microtubule stabilization), gemcitabine (antimetabolite, DNA synthesis inhibition), topotecan (topoisomerase I inhibitor), pegylated liposomal doxorubicin/PLD (anthracycline, DNA intercalation and topoisomerase II inhibition). Targets: CDH6-positive tumor cells, pathways: cell-adhesion/CDH6-mediated internalization, nuclear DNA via topo I inhibition.